Mandate

Vinge advises Calliditas Therapeutics in connection with a directed share issue

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with a directed share issue whereby the company will raise proceeds of approximately SEK 324 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström and Benjamin Vafaeian.

Related

Vinge has advised SBP Kredit AB (publ) in connection a securitisation with a Nordic bank as senior lender

The agreement covers a total amount of SEK 1 billion and creates conditions for significantly increased lending capacity. The agreement has been structured in accordance with the EU Securitisation Regulation and enables qualified loans to be continuously transferred to a special purpose vehicle within the SBP group.
September 14, 2026

Vinge has advised Northmill Group AB in connection with the issuance of tier 2 capital bonds (T2)

Vinge has advised Northmill Group AB in connection with its successful issuance of SEK 150 million tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 475 basis points.
September 11, 2026

Vinge advises IK Partners and Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik

Vinge has advised IK Partners and its portfolio company Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik, a company specialising in refrigeration technology and refrigeration services in southern Sweden. The acquisition strengthens Francks Kylindustri’s position in southern Sweden and broadens the group’s offering within the refrigeration industry.
September 11, 2026